Allergan forecasts second-half revenue above $8 billion

(Reuters) - Drugmaker Allergan Plc (AGN.N) said it expected revenue to be greater than $8 billion in the second half to reflect the divesture of its global generics business to Teva Pharmaceuticals Industries Ltd (TEVA.TA) (TEVA.N).

The company said it intends to report its global generics business as discontinued operations in the third quarter.

(Reporting by Rosmi Shaji in Bengaluru)

Advertisement